- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.
EP: 1.Lp(a) in ASCVD and Guideline Recommendations
EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis
EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease
EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime
EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening
EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk
EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations
EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing
EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing
EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing
EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels
EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment
EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake
Video content above is prompted by the following:
- Currently, how prevalent is Lp(a) testing in the US, both in the overall population and among those with established ASCVD?
- How common is Lp(a) testing within the health plans that you work with?
- How can payers, population health decision makers working at health systems, and provider groups infuse Lp(a) testing into their larger population health management infrastructure?
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
